The use of Mucitus (Erdostein) in the treatment of broncho-pulmonary diseases in the practice of a family doctor
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Diseases of the broncho-pulmonary apparatus are the important medical and social problem due to the high prevalence, disability and mortality. If the process of formation of the bronchial secretion and its progress in the proximal direction is disrupted, mucolytic therapy with stimulation of mucus excretion, dilution, reduction of its formation and rehydration is actual.
The objective: to reveal the therapeutic effectiveness and safety of the drug Mucitus in the complex treatment of acute and chronic bronchitis.
Materials and methods. The study included 37 patients (group I) with acute bronchitis (n=10), or exacerbation of chronic bronchitis (n=23) and COPD (n=4). The control group (group II) included 12 patients: with acute bronchitis - 5, with exacerbation of chronic bronchitis – 7 people.
Results. The effectiveness of Mucitus was assessed by changing the frequency of coughing attacks during 8 days of therapy, safety - based on monitoring data of the patient’s condition, frequency and nature of adverse reactions, laboratory examination data, assessment of the subjective condition of the patient.
Conclusion.The treatment with ergodein led to an improvement in the patient’s condition, there was a decrease in the frequency of coughing attacks on the 8th day of therapy by more than 70% of the initial value. During the treatment adverse negative reactions with mucitus were not recorded, tolerability is characterized as «good». Mucitus (ergosteine), capsules produced by PJSC Macleods can be recommended for use as an effective and safe mucolytic agent.##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
World report on ageing and health [Електронний ресурс] // World Health Organization. – 2015. – Режим доступу до ресурсу: http://www.who.int/ageing/publications/world-report-2015/en/.
Родіонова В.В., Глиняная Л.А., Родионова В.В., Бут Н.А., Собко С.В. Комплексна оцінка тяжкості перебігу ХОЗЛ у пацієнтів, працюючих у шкідливих умовах праці // Тези наукових доповідей науково-практичної конференції до 100-річчя з дня народження професора І.І. Крижанівської; Дніпропетровськ, 15-16 травня 2013. – С. 59–60.
The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUAUFE Study/ Moretti M„ Bottrighi P., Dallari R. et al. //Drugs Exp. Clin. Res. – 2004. – Vol. 30, № 4. – P. 143–152.
Aubier М, Berdah L Multicenter, controlled, double-blind study of the efficacy and tolerance of Vectrine (erdostein) versus placebo in the treatment of stabilized chronic bronchitis with hypersecretion //Rev. Mai. Respir. – 1999. – Vol. 16, № 4. – P. 521–528.
Global Initiative for Chronic Obstructive Lung Disease (GOLD) The Global Strategy for tre Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2018 report) https://goldcopd.org/
Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children / Balli F„ Bergamini B„ Calistru R etal. //Int J. Clin. Pharmacol. Ther. – 2007. – Vol. 45, № 1. – Р. 16–22. https://www.doi.org/10.5414/CPP45016
Mucolytic and antitussive effects of erdosteine /Hosoe H„ Kaise ,, Ohmori K. et al. //J. Pharm. Pharmacol. – 1999. – M51. – P. 959–66. http://dx.doi.org/10.1211/0022357991773230
